mucosal membrane dryness
Products that synergistically combine plasma or plasma derivatives with chitosan offer a promising approach to the treatment of mucosal membrane dryness, particularly in the areas of oral and vaginal dryness.
Plasma, especially when it’s concentrated as in platelet-rich plasma (PRP), is rich in growth factors and proteins. These components are known to promote cell proliferation, tissue regeneration, and repair, making them beneficial for mucosal health. Additionally, the inherent composition of plasma naturally hydrates dry mucosal membranes.
Our chitosan ingredient is recognized for its strong mucoadhesive properties. When applied to mucosal surfaces, it may prolong contact time of therapeutic agents like those from plasma. Furthermore, chitosan may enable a controlled and sustained release, optimizing the benefits of incorporated agents, such as plasma-derived proteins.
When combined, these two components may offer enhanced benefits. The tissue-repairing benefits of plasma-derived products, combined with the sustained action of chitosan, potentially provide both relief and long-lasting therapeutic action.
Beyond just the delivery mechanism, the combination may also create a barrier. Chitosan, when combined with plasma-derived products, may form a protective barrier on the mucosa, which should provide hydration and continually supply the mucosa with growth factors and proteins.
We are evaluating disease and region-specific applications. In the case of mouth dryness, a gel or spray containing both plasma derivatives and chitosan could relieve the discomfort of dryness, promote the healing of mucosal lesions, and offer sustained hydration. For vaginal dryness, gels or suppositories that incorporate both these components may be effective.
learn more about:
our products
Our therapeutic formulation is suitable for a variety of products, including liquid eye drops, gels, ointments, contact lenses, contoured bandages, and wound dressings. Initially, ECI is pursuing ophthalmic indications for neurotrophic keratopathy (NK) and dry eye disease (DED).
ECI’s pipeline includes indications for ophthalmic burns, epithelial defects, endothelial diseases, limb stem cell deficiency, ocular graft-versus-host disease (GvHD), corneal abrasions, and chronic wounds.
our platform
Our platform leverages growth factors derived from donated human platelet-rich plasma and proprietary hyaluronic acid (HA) or chitosan. The tissue-repairing benefits of plasma-derived products, combined with the sustained action and impact of HA or chitosan, may provide relief and long-lasting therapeutic action.
our platform
product safety
The safety of our products is paramount. To ensure that our products are as safe as possible, pathogen inactivation and removal technologies like the INTERCEPT Blood System for Plasma and nanofiltration have been incorporated into our manufacturing process.
ECI has met with the FDA and aligned on an orthogonal (multi-step) safety plan meeting all regulatory requirements.